MoonLake Immunotherapeutics Stock 12‑Month Price Target Cut to $30, Implies 156% Upside

What happened

Estimates from 13 analysts lowered MoonLake Immunotherapeutics’ average 12-month share-price target from $30.23 to $30. The forecasts range from $6 to $70 per share. Based on the Nov. 3 closing price, the updated target implies approximately 156% potential upside. The consensus rating remains Buy among 15 analysts.

Confirmed

Global impact / market context

The lower average target signals a modest reduction in analysts’ expected value, while the stated 156% potential upside still points to a large gap between the target and the Nov. 3 closing price. Such estimates can shape investor expectations, but they are forecasts, not guaranteed returns.

Analyst inference

Analyst views are not uniform: forecasts span $6 to $70 per share, and the 15-analyst rating split includes 11 Buys, two Holds and two Sells. That range indicates substantial disagreement about the company’s prospects, even though the overall rating remains Buy.

Confirmed

What to watch

1. Future analyst target changes could show whether the average estimate continues to decline or begins to recover; the article provides no explanation for the current reduction. Analyst inference
2. The forecast range and rating split may change as analysts revise their estimates, potentially narrowing or widening the gap in views about MoonLake’s share value. Analyst inference
3. The stated upside uses the Nov. 3 closing price as its reference; changes in the share price would alter the implied upside even if the target stayed at $30. Confirmed

Evidence

• Original source link unavailable